Biosynex Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Larry Abensur

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	9.3yrs
CEO ownership	6.2%
Management average tenure	no data
Board average tenure	9.3yrs

Recent management updates

Recent updates

CEO

Larry Abensur

9.3yrs

Tenure

Mr. Larry Abensur has served as a Director at Biosynex S.A. since June 24, 2015 and serves as the Chief Executive Officer at Biosynex SA. He serves as the Chairman of Biosynex S.A. Mr. Abensur serves as th...

Board Members

Name	Position	Tenure	Compensation	Ownership
Larry Abensur	Chairman & CEO	9.3yrs	no data	6.2% € 2.8m
Thierry Paper	Deputy CEO & Director	9.3yrs	€96.00k	0.99% € 444.7k
Thomas Lamy	Deputy CEO & Director	9.3yrs	no data	1.56% € 698.8k
Felix Agbalika	Member of Scientific Advisory Board	no data	no data	no data
Emmanuel Drouet	Member of Scientific Advisory Board	no data	no data	no data
Denis Gallot	Member of Scientific Advisory Board	no data	no data	no data
Vincent Sapin	Member of Scientific Advisory Board	no data	no data	no data
Marc Noizet	Member of Scientific Advisory Board	no data	no data	no data
Elie Fraenckel	Director	no data	no data	no data

9.3yrs

Average Tenure

Experienced Board: 0DL's board of directors are considered experienced (9.3 years average tenure).

Biosynex Management

Management criteria checks 1/4

Key information

Recent management updates

Biosynex SA, Annual General Meeting, Jun 07, 2024

No independent directors

No independent directors

Recent updates

New major risk - Share price stability

Biosynex SA, Annual General Meeting, Jun 07, 2024

Full year 2023 earnings released: €3.45 loss per share (vs €1.53 profit in FY 2022)

New minor risk - Shareholder dilution

First half 2023 earnings released: €1.94 loss per share (vs €2.99 profit in 1H 2022)

New minor risk - Market cap size

New major risk - Earnings quality

Biosynex SA (ENXTPA:ALBIO) acquired 57.33% interest in ProciseDx Inc. from Nestlé HealthCare Nutrition, Inc., other shareholders, employees, former employees and investors.

Biosynex SA (ENXTPA:ALBIO) signed an agreement to acquire 57.33% interest in ProciseDx Inc. from Nestlé HealthCare Nutrition, Inc., other shareholders, employees, former employees and investors.

Biosynex SA (ENXTPA:ALBIO) acquired Eye Care activity from LABORATOIRES INNOXA.

Investor sentiment improves as stock rises 16%

Investor sentiment deteriorates as stock falls 24%

Full year 2022 earnings released

Biosynex SA (ENXTPA:ALBIO) entered into a definitive merger agreement to acquire Chembio Diagnostics, Inc. (NasdaqCM:CEMI) for $17.2 million.

Investor sentiment improved over the past week

Biosynex SA (ENXTPA:ALBIO) acquired 75% stake in Medkoncept A/S.

Investor sentiment improved over the past week

No independent directors

First half 2022 earnings released

Biosynex SA (ENXTPA:ALBIO) acquired Doc2u SAS on October 12, 2022.

Biosynex SA (ENXTPA:ALBIO) alongside the two founders acquired Bhr Pharmaceuticals Limited.

Upcoming dividend of €2.00 per share

Full year 2021 earnings released: EPS: €10.08 (vs €3.52 in FY 2020)

No independent directors

Biosynex SA (ENXTPA:ALBIO) acquired PrimaDiag SAS.

Biosynex SA (ENXTPA:ALBIO) acquired Para'kito.

Full year 2021 earnings released

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Biosynex SA (ENXTPA:ALBIO) signed a binding letter of offer to acquire Human Health Business of Enalees.

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Biosynex SA (ENXTPA:ALBIO) commences an Equity Buyback Plan for 10% of its issued share capital, for €4.5 million, under the authorization approved on June 8, 2020.

Full year 2020 earnings released: EPS €3.43 (vs €0.12 in FY 2019)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Biosynex SA has completed a Follow-on Equity Offering in the amount of €15 million.

CEO

Tenure

Board Members

Average Tenure